|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:David_A._Ricks
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
532457108
|
|
gptkbp:dividendPaying
|
yes
|
|
gptkbp:foundedBy
|
gptkb:Eli_Lilly
|
|
gptkbp:foundedYear
|
1876
|
|
gptkbp:headquartersLocation
|
gptkb:Indianapolis,_Indiana,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eli Lilly and Company
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
US5324571083
|
|
gptkbp:logo
|
Eli Lilly and Company logo.svg
|
|
gptkbp:marketCap
|
over $500 billion (2024)
|
|
gptkbp:memberOf
|
gptkb:Pharmaceutical_Research_and_Manufacturers_of_America
|
|
gptkbp:NAICS
|
325412
|
|
gptkbp:netIncome
|
$5.2 billion (2022)
|
|
gptkbp:notableEmployee
|
gptkb:George_H._Hitchings
gptkb:Paul_Janssen
|
|
gptkbp:notableEvent
|
Acquired ImClone Systems in 2008
Developed first commercially available insulin
Developed first mass-produced polio vaccine
Launched Mounjaro (tirzepatide) in 2022
Spun off Elanco in 2018
|
|
gptkbp:notableProduct
|
gptkb:Alimta
gptkb:Cymbalta
gptkb:Emgality
gptkb:Humalog
gptkb:Mounjaro
gptkb:Prozac
gptkb:Trulicity
gptkb:Verzenio
gptkb:Zyprexa
|
|
gptkbp:numberOfEmployees
|
approximately 41,000 (2023)
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:rank
|
gptkb:Fortune_500
|
|
gptkbp:researchInterest
|
gptkb:diabetes
immunology
neuroscience
oncology
|
|
gptkbp:revenue
|
$28.5 billion (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:SIC
|
2834
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:LLY
|
|
gptkbp:subsidiary
|
gptkb:ImClone_Systems
Elanco (spun off in 2018)
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.lilly.com/
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_Award_in_Biological_Chemistry
gptkb:Sigilon_Therapeutics
gptkb:Indianapolis,_Indiana
|
|
gptkbp:bfsLayer
|
4
|